Jefferies & Co

Jefferies is out with an analyst note this morning that lowers estimates and the price target for Parexel International (NASDAQ: PRXL), though maintains the Buy rating on the stock. Jefferies has a $28.00 price target; down from $29.00. Analysts cited the company recently updating their FY11...

Jefferies & Co. is out with an analyst note this morning that reiterates their Buy rating on shares of Biogen Idec (NASDAQ: BIIB); they have a price target of $63.00 on the stock. Jefferies analysts cited a recent Bayer lawsuit that suggests a potential royalty upside for Biogen. The lawsuit...

Register for the LA Trader's Expo for Free Here! Jefferies & Co. is out with an analyst note this morning that is reiterating their Hold rating on shares of Charles River Laboratories (NYSE: CRL); they have a $37.00 price target. Jefferies cited the recent analyst call, which was done to...

Jefferies & Co. is out with an analyst note this morning where they reiterate their Buy rating on shares of DuPont (NYSE: DD). They have a $44.00 price target on the stock. Jefferies analysts cited a recent meeting with DuPont’s chair and CEO, where they addressed end market dynamics, M&A...

Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the Jefferies 2010 Global Life Sciences Conference in New York, NY. Jefferies 2010 Global Life...

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the 9th Annual Needham Healthcare Conference in New York on Wednesday, June 9, 2010 at 10:40 a.m. ET and the Jefferies 2010 Global Life Sciences...

In a report released today by Jefferies & Co., the firm's analysts reiterated their Buy rating and $31.00 price target on shares of Seadrill Ltd. (NASDAQ: SDRL). The firm, however, is lowering their 2Q10 EPS estimates to $0.60 from $0.65 due primarily to downtime guidance on several rigs....

Jefferies & Co. released a research note this morning reiterating their Buy rating and $16.00 price target on shares of Calpine Corp. (NYSE: CPN). The analysts wrote that "we believe Calpine should trade at a premium to other merchant generators since it is less exposed to changes in the...

Jefferies & Co. is out with an analyst note this morning that reiterates their Hold rating on shares of Quality Systems (NASDAQ: QSII). They have a $62.00 price target on the stock. Jefferies analysts said that the company’s most recent earnings report was mixed with EPS of $0.45, which was...

Jefferies is out with an analyst note this morning that is reiterating their Buy rating on shares of Mellanox Technologies (NASDAQ: MLNX). They also have a $30.00 price target on the stock. Jefferies cited the June 2010 edition of the Top500, a semi-annual list of the fastest supercomputers in the...

Analysts at Jefferies & Co reiterate their "buy" rating on Thermo Fisher Scientific (NYSE: TMO), while reducing their estimates for the company. The target price for TMO is set to $63. According to the analysts, TMO's initial 2011 “core operating outlook along with longer-term base operating...

Jeffries & Co. is out with an investor note this morning that is reiterating their thesis, rating, and price target on shares of Corning (NYSE: GLW). They have a Buy rating on GLW with a price target of $23.00. Jeffries analysts cited low LCD TV inventory levels in North America; they said...

Jefferies & Co. is out with an investor note this morning that is reiterating their Buy rating on shares of Nalco Holding (NYSE: NLC). They have a price target of $30.00. Jefferies analysts said that “Nalco recently released details defending the safety of its dispersant, COREXIT 9500, which...

Bristol-Myers Squibb (NYSE: BMY) has transformed its business by trading in lower margin and growth assets for investments in biotech acquisitions and to develop its pipeline. The company has recently announced positive Phase II data for Ipilimumab from a 203-patient study in Stage IIIb-IV non-...